Parkinson's
disease is a progressive condition that is characterized by bradykinesia,
muscular rigidity, tremor, and postural instability. As the second most common
neurodegenerative disorder, Parkinson's disease may affect individuals of any
age but prevalence is increased with age and it is most common in the elderly.
Dopaminergic
therapies have been fairly effective in treating bradykinesia, but several
unmet needs remain. Some needs will be met during the forecast period from 2012-2022,
while others, such as the need for disease-modifying drugs, will remain.
GlobalData
expects that advancements will be made in levodopa administration and that four
new molecular entities will be introduced to the market by 2022, these factors
along with increased patient numbers from an aging population will drive the
market during the forecast period.
Read Complete Report with TOC @ http://www.radiantinsights.com/research/duodopa-parkinson-s-disease-forecast-and-market-analysis-to-2022
Developed by
AbbVie, Duodopa is a gel composed of carbidopa/levodopa and administered via a
pump into the intestine, where the drug is absorbed. It is approved for
patients with advanced Parkinson's disease with motor fluctuations.
Continual
infusion provides steady state serum drug levels, while the patient experiences
relative freedom from oral medications and optimal control of motor symptoms,
including ON-OFF and dyskinesias.
Scope
- Overview
of Parkinson's disease, including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the competitive
landscape.
- Detailed
information on Duodopa including product description, safety and efficacy
profiles as well as a SWOT analysis.
- Sales
forecast for Duodopa for the top seven countries from 2012 to 2022.
- Sales
information covered for the US, France, Germany, Italy, Spain, the UK and
Japan.
Reasons to buy
- Understand
and capitalize by identifying products that are most likely to ensure a robust
return
- Stay ahead
of the competition by understanding the changing competitive landscape for
Parkinson's disease
-
Effectively plan your M&A and partnership strategies by identifying drugs
with the most promising sales potential
- Make more
informed business decisions from insightful and in-depth analysis of Duodopa
performance
- Obtain
sales forecast for Duodopa from 2012-2022 in the top seven countries (the US,
France, Germany, Italy, Spain, the UK and Japan).
About Us
Radiant Insights is a platform for companies
looking to meet their market research and business intelligence requirements.
We assist and facilitate organizations and individuals procure market research
reports, helping them in the decision making process. We have a comprehensive
collection of reports, covering over 40 key industries and a host of micro
markets. In addition to over extensive database of reports, our experienced
research coordinators also offer a host of ancillary services such as, research
partnerships/ tie-ups and customized research solutions.
For more
information visit: Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Blog
URL: http://www.esorics2010.org/
No comments:
Post a Comment